Alfred Ebert, MD
Psychiatry · Clinton, SCNPI 1336231851
Payments from drug & device makers
Across 966 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$1K
- plus $4K from 19 others
What the payments were for
- Food & beverage$14,66099%
- Education$1961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 208 | $2,421 |
| Otsuka America Pharmaceutical, Inc. | 144 | $2,407 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 114 | $1,899 |
| Teva Pharmaceuticals USA, Inc. | 95 | $1,460 |
| Johnson & Johnson | 93 | $1,408 |
| Neurocrine Biosciences, Inc. | 69 | $1,278 |
| Alkermes, Inc. | 51 | $994 |
| Vanda Pharmaceuticals Inc. | 36 | $578 |
| Sunovion Pharmaceuticals Inc. | 56 | $576 |
| Lundbeck LLC | 20 | $369 |
| E.r. Squibb & Sons, L.L.C. | 19 | $337 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $262 |
| Corium, LLC | 10 | $161 |
| Ironshore Pharmaceuticals Inc. | 6 | $122 |
| Axsome Therapeutics, Inc. | 7 | $118 |
| Acadia Pharmaceuticals Inc | 1 | $74 |
| Tris Pharma Inc | 3 | $73 |
| Supernus Pharmaceuticals, Inc. | 4 | $71 |
| Avanir Pharmaceuticals, Inc. | 4 | $57 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Shire North American Group Inc | 3 | $42 |
| Bristol Myers Squibb | 1 | $33 |
| Indivior Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$243
- ABILIFY ASIMTUFII$243
- VRAYLAR$125
- REXULTI$124
- INGREZZA$114
How this compares
$14,856 in reported general payments places this provider in the 90th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 301 | $857,504 |
| Invega TrinzaPaliperidone Palmitate | 59 | $485,151 |
| Abilify MaintenaAripiprazole | 99 | $279,852 |
| IngrezzaValbenazine Tosylate | 30 | $240,842 |
| RexultiBrexpiprazole | 121 | $184,816 |
| CaplytaLumateperone Tosylate | 110 | $176,716 |
| AustedoDeutetrabenazine | 16 | $176,659 |
| UzedyRisperidone | 31 | $162,605 |
| VraylarCariprazine Hcl | 63 | $97,525 |
| FanaptIloperidone | 32 | $93,369 |
| AristadaAripiprazole Lauroxil | 24 | $76,139 |
| AuvelityDextromethorphan Hbr/Bupropion | 41 | $45,096 |
| TrintellixVortioxetine Hydrobromide | 66 | $38,681 |
| Lurasidone Hcl | 95 | $22,763 |
| Clozapine | 84 | $13,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,408 | $1,342,655360 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,407 | $464,668220 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $1,460 | $339,26447 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,278 | $240,84230 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,899 | $176,716110 claims |
| AbbVieVraylar | $2,421 | $97,52563 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $578 | $93,36932 claims |
| Alkermes, Inc.Aristada | $994 | $76,13924 claims |
| Axsome Therapeutics, Inc.Auvelity | $118 | $45,09641 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $262 | $38,68166 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $18 | $5,57912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Clinton
- Jacobo MintzerCharleston$4.9M
- Paul RobbinsSummerville$1.2M
- Brittany AlbrightMount Pleasant$691K
- Eduardo CifuentesCharleston$675K
- Veronica RidpathFlorence$364K
- Mark GeorgeCharleston$332K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Thomas UhdeCharleston$205K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.